GoAI
Get started
Illumina, Inc. logo

Illumina, Inc.

ILMN

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$219.4

+$6.16 · +2.89%

Aug 21, 4:00 PM ET

ILMN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

84

Deep Value

Momentum

72

Gaining

Sentiment

54

Mixed

Risk resilience

62

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Jacob Thaysen
Listed since
Jul 28, 2000
Employees
8,600

Market position

Day range

Current $219.4

52-week range

Current $219.4

Open
$212.4
Previous close
$213.24
Volume
1.92M
1.03× average
Average volume
1.87M
Average daily volume
Market cap
33.2B USD
Beta
1.46
Market reference 1
50-day average
$187.54
+16.99% above average
200-day average
$146.97
+49.28% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
21.98B USD
P/E (TTM)
40.55×
P/B (TTM)
11.67×
P/S (TTM)
7.39×
EV / EBITDA
15.09×
Earnings yield
4.08%
Free cash flow yield
4.47%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
66.79%
Operating margin
20.97%
Net margin
18.36%
Return on equity
31.22%
Return on assets
12.79%
Return on invested capital
12.00%

Financial health

Debt / equity
0.89×
Current ratio
2.08×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends86%20%-46%-113%Gross margin, FY2021: 69.69%Gross margin, FY2022: 64.83%Gross margin, FY2023: 60.92%Gross margin, FY2024: 65.44%Gross margin, FY2025: 66.69%Operating margin, FY2021: -2.72%Operating margin, FY2022: -91.16%Operating margin, FY2023: -23.73%Operating margin, FY2024: -19.05%Operating margin, FY2025: 19.92%Net margin, FY2021: 16.84%Net margin, FY2022: -96.07%Net margin, FY2023: -25.78%Net margin, FY2024: -27.97%Net margin, FY2025: 19.59%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 69.69%. Gross margin FY2022 64.83%. Gross margin FY2023 60.92%. Gross margin FY2024 65.44%. Gross margin FY2025 66.69%. Operating margin FY2021 -2.72%. Operating margin FY2022 -91.16%. Operating margin FY2023 -23.73%. Operating margin FY2024 -19.05%. Operating margin FY2025 19.92%. Net margin FY2021 16.84%. Net margin FY2022 -96.07%. Net margin FY2023 -25.78%. Net margin FY2024 -27.97%. Net margin FY2025 19.59%.

Income trends

Revenue

4.34B USD-0.78%

Operating income

864M USD+1.7B USD

Net income

850M USD+2.07B USD
Income trends across reported periods5.48B USD1.89B USD−1.71B USD−5.3B USDRevenue, FY2021: 4.53B USDRevenue, FY2022: 4.58B USDRevenue, FY2023: 4.5B USDRevenue, FY2024: 4.37B USDRevenue, FY2025: 4.34B USDOperating income, FY2021: −123M USDOperating income, FY2022: −4.18B USDOperating income, FY2023: −1.07B USDOperating income, FY2024: −833M USDOperating income, FY2025: 864M USDNet income, FY2021: 762M USDNet income, FY2022: −4.4B USDNet income, FY2023: −1.16B USDNet income, FY2024: −1.22B USDNet income, FY2025: 850M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.53B USD. Revenue FY2022 4.58B USD. Revenue FY2023 4.5B USD. Revenue FY2024 4.37B USD. Revenue FY2025 4.34B USD. Operating income FY2021 −123M USD. Operating income FY2022 −4.18B USD. Operating income FY2023 −1.07B USD. Operating income FY2024 −833M USD. Operating income FY2025 864M USD. Net income FY2021 762M USD. Net income FY2022 −4.4B USD. Net income FY2023 −1.16B USD. Net income FY2024 −1.22B USD. Net income FY2025 850M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.34B USD4.37B USD4.5B USD4.58B USD4.53B USD
Cost of goods sold1.45B USD1.51B USD1.76B USD1.61B USD1.37B USD
Gross profit2.89B USD2.86B USD2.74B USD2.97B USD3.15B USD
Research and development951M USD1.17B USD1.35B USD1.32B USD1.19B USD
Selling, general, and administrative1.08B USD1.09B USD1.61B USD1.3B USD2.09B USD
Operating expenses2.03B USD3.69B USD3.81B USD7.15B USD3.28B USD
Interest income40M USD46M USD58M USD11M USD—
Interest expense101M USD100M USD77M USD26M USD61M USD
Depreciation and amortization270M USD354M USD432M USD394M USD251M USD
Operating income864M USD−833M USD−1.07B USD−4.18B USD−123M USD
Net income850M USD−1.22B USD−1.16B USD−4.4B USD762M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+100.31%
11 comparable reports
Latest EPS result
1.31
Estimate 1.23 · Beat by 6.50%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.441.231.010.8Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 0.86, estimate 0.92, surprise -6.52%, Miss. Q2 2025, reported May 8, 2025: actual 0.97, estimate 0.94, surprise +3.19%, Beat. Q3 2025, reported Jul 31, 2025: actual 1.19, estimate 1.02, surprise +16.67%, Beat. Q4 2025, reported Oct 30, 2025: actual 1.34, estimate 1.17, surprise +14.53%, Beat. Q1 2026, reported Feb 5, 2026: actual 1.35, estimate 1.24, surprise +8.87%, Beat. Q2 2026, reported Apr 30, 2026: actual 1.15, estimate 1.05, surprise +9.52%, Beat. Q3 2026, reported Jul 30, 2026: actual 1.31, estimate 1.23, surprise +6.50%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.38, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.21B1.13B1.05B979.06MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual 1.1B USD, estimate 1.07B USD, surprise +3.00%, Beat. Q2 2025, reported May 8, 2025: actual 1.04B USD, estimate 1.03B USD, surprise +1.52%, Beat. Q3 2025, reported Jul 31, 2025: actual 1.06B USD, estimate 1.06B USD, surprise -0.56%, Miss. Q4 2025, reported Oct 30, 2025: actual 1.08B USD, estimate 1.07B USD, surprise +1.65%, Beat. Q1 2026, reported Feb 5, 2026: actual 1.16B USD, estimate 1.12B USD, surprise +3.60%, Beat. Q2 2026, reported Apr 30, 2026: actual 1.09B USD, estimate 1.07B USD, surprise +1.66%, Beat. Q3 2026, reported Jul 30, 2026: actual 1.16B USD, estimate 1.13B USD, surprise +2.51%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.15B USD, surprise —, Comparison unavailable.

ILMN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ILMN

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
1.01B
Weight
0.79%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.77+0.52%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
938.81M
Weight
0.04%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
677.59M
Weight
0.37%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
357.43M
Weight
0.37%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
240.6M
Weight
2.27%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Invesco S&P MidCap Quality ETF logoInvesco S&P MidCap Quality ETFXMHQ
Market value
239.2M
Weight
4.24%
AUM
5.67B USD
Expense ratio
0.31%
Price / 1D
$119.27+0.45%
State Street SPDR S&P MIDCAP 400 ETF Trust logoState Street SPDR S&P MIDCAP 400 ETF TrustMDY
Market value
236.28M
Weight
0.89%
AUM
26.72B USD
Expense ratio
0.23%
Price / 1D
$699.6+0.48%
Vanguard Morningstar Small-Cap Value ETF logoVanguard Morningstar Small-Cap Value ETFVBR
Market value
215.22M
Weight
0.31%
AUM
68.3B USD
Expense ratio
0.05%
Price / 1D
$249.18+0.68%

Continue in GoAI

Research ILMN

research.disclaimer